by jtcir-auto | Mar 23, 2023 | Press Releases
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025- Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go...
by jtcir-auto | Mar 16, 2023 | Press Releases
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
by jtcir-auto | Mar 16, 2023 | Press Releases
Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
by jtcir-auto | Jan 17, 2023 | Press Releases
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision...
by jtcir-auto | Jan 10, 2023 | Press Releases
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing...
by jtcir-auto | Jan 10, 2023 | Press Releases
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing...